Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)

Inclusion Criteria: Male and female subjects will be eligible for participation in this study if: * they are toddlers, aged 12 to 18 months * they are clinically healthy (i.e. the physician would have no reservations vaccinating with a MenC conjugate vaccine, and/or PCV7 outside the scope of a clinical trial) * their parents/legal guardian(s) understand the nature of the study, agree to its provisions, and provide written informed consent * their parents/legal guardian(s) agree to keep a Subject Diary * they have received a complete primary series of pneumococcal conjugate vaccine (3 vaccinations with PCV7 in the first year of life according to the official vaccination calendar recommendations) Exclusion Criteria: Subjects will be excluded from participation in this study if: * they have a history of any vaccine-related contraindicating event, e.g. serious reactions after first application of a PCV7 vaccine or high fever \>= 40ºC associated with any vaccination, or generalized allergic reaction within 48 hours of a first application of vaccine * they have a known sensitivity or allergy to any components of the vaccines * they have previously been vaccinated with MenC vaccine * they have already received a PCV 7 booster (4th vaccination) * they have a rash or other dermatological condition at the injection site which could interfere with injection site reaction evaluation * they suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. sy…